Phase 2 N=383 An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value) — -0.61; -0.80; -0.79; -0.88 percent HbA1C
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=49 Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study
Type 1 Diabetes
Primary: Hypoglycemia Outcome: Percentage of Nights With Sensor Glucose Value </=60 mg/dl — 21; 33 percentage of nights — p=<0.001
Phase 3 N=241 Cognitive Therapy for Recurrent Depression
Depression
Primary: Depressive Relapse or MDD — 18; 18.3; 32.7 % patients who relapsed — p=.42
Phase 3 N=905 The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) — 0.205; 0.093 Liters — p=<0.001
Phase 3 N=301 Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 — 0.15; -0.70; -0.89 Percentage of HbA1c in the blood — p=<0.0001
Phase 3 N=272 Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value) — -0.74; -0.76; 0.29 percent HbA1C
Phase 2 N=29 Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
Bladder Cancer
Primary: Percentage of Patients With Complete Pathologic Response After 3 Cycles of Treatment — 27.3 percentage of patients
Phase 3 N=60 (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets
Colitis, Ulcerative
Primary: The Percentage of Patients Achieving Clinical Remission — 25 percentage of patients
Phase 2 N=42 Phase II Trial of Pentostatin and Targeted Busulfan
Hematologic Malignancies
Primary: Incidence of Greater Than or Equal to 50% Donor Chimerism — 100 percentage of participants
Phase 3 N=914 A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)
Allergy
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 321; 130 Participants — p=0.005
Phase 2 N=16 Digoxin for Recurrent Prostate Cancer
Prostate Cancer
Primary: Rate of Positive PSADT Outcome — 5 participants
Phase 3 N=284 Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)
Idiopathic Restless Legs Syndrome
Primary: International Restless Legs Syndrome Rating Scale (IRLS) Total Score — -11.6; -14.3; -14.6 Scores on a scale
N/A N=252 Assessment of Pain in People With Thalassemia
Thalassemia
Primary: Prevalence of Pain — 75; 7; 11 participants — p=0.45
Phase 2 N=40 Cox-2 Inhibition in Radiation-induced Oral Mucositis
Oral Mucositis
Primary: Clinical Oral Mucosal Injury Score at Cumulative Radiation Dose of 5000 cGy — 1.42; 1.36 units on a scale
Phase 2 N=198 A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.
Asthma
Primary: Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period — -0.004; 0.135; 0.178; 0.201 Liter…